Skip to main content

Table 3 Physiologic and Subjective Measures – Summary of Peak Changes (Mean ± SD for 12 Subjects)

From: A Phase 1 Trial of pharmacologic interactions between transdermal selegiline and a 4-hour cocaine infusion

 

Session 1

Session 2

Measures

Peak

Mean ± SD

Peak Time

(Hr Postdose)

Peak

Mean ± SD

Peak Time

(Hr Postdose)

Physiologic Measures

    

Systolic Blood Pressure (mmHg)

17 ± 8

2.2 ± 1.9

17 ± 9

1.9 ± 1.7

Diastolic Blood Pressure (mmHg)

10 ± 5

2.8 ± 2.4

12 ± 6

2 ± 2

Heart Rate (beats/min)

26 ± 10

0.8 ± 0.9

27 ± 12

0.9 ± 1.7

Rate Pressure Product (SBP*HR)

4224 ± 1638

1.4 ± 1.5

4437 ± 2333

0.9 ± 1.6

Respiration Rate (inhal/min)

3.8 ± 4.0

0.9 ± 1.3

3.8 ± 3.6

0.4 ± 0.3

Skin Temperature (°C)

-5.4 ± 2.7

0.8 ± 0.4

-5 ± 3.2

1.0 ± 1.2

Core Temperature (°C)

0.7 ± 0.2

4.5 ± 1.6

0.7 ± 0.5

4.2 ± 1.9

Subjective Measures

    

Global Intoxication (0–100)

57 ± 27

0.7 ± 1

53 ± 23

0.6 ± 0.9

Cocaine Craving (0–100)

33 ± 25

1.1 ± 1.3

20 ± 21

0.6 ± 0.7

Good Drug Effect (0–100)

66 ± 23

0.9 ± 1.5

60 ± 21

1 ± 1.3

Bad Drug Effect(0–100)

46 ± 31

1.9 ± 2.3

55 ± 25

1.4 ± 1.9

POMS Scales

    

Tension (0–28)

7.5 ± 6.1

1 ± 0

4.8 ± 3.9

1 ± 0

Depression (0–64)

3 ± 6.5

3 ± 0

1.5 ± 2.4

3 ± 0

Anger (0–28)

2.8 ± 6.4

6 ± 0

-2.1 ± 5.7*

6 ± 0

Vigor (0–32)

-3.6 ± 3.4

6 ± 0

-3.9 ± 6.1

6 ± 0

Confusion (0–20)

2.5 ± 2.8

6 ± 0

2.7 ± 4.7

3 ± 0

Fatigue (0–28)

5.9 ± 5.9

6 ± 0

2.8 ± 5.3

6 ± 0

  1. * Significantly different from Session 1 (p < 0.03).
  2. Session 1: First cocaine infusion, performed on day 1, before selegiline administration.
  3. Session 2: Second cocaine infusion, performed on day 11, following one week of selegiline administration by STS patch (6 mg/24 hours). Infusion began 2 hours after application of the selegiline daily patch.